An important message from NCRVA regarding coronavirus (COVID-19).

COVID-19 & Your Appointment
Northern California Retina Vitreous Associates logo for print
  • Daly City: 650-994-2100
  • San Mateo: 650-340-0111
  • Mountain View: 650-963-3460
  • Monterey: 831-373-6280
  • East San Jose: 408-251-3500
  • West San Jose: 408-356-8818
Reset Text size:
Reset Text size:

Clinical Trials

Diabetic Macular Edema

Active Studies

GLIMMER (Kodiak)

A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).

KALAHARI (Oxurion)

A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular oedema (DME).

KSI-CL-101 (Kodiak Sciences)

A Phase 1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects with wet Age-related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion.

RHINE GR40398 (Roche)

A phase 3, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with Diabetic Macular Edema.

RHONE (Roche)

A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA.


Completed Studies

BOULEVARD (Genentech)

A multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, parallel group, 28-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with diabetic macular edema.

 

DEL MAR (Allegro)

A 6 month, phase 2, multicenter, randomized, controlled, double-masked clinical trial designed to evaluate the safety and exploratory efficacy of Luminate (ALG-1001) as compared to Avastin in the treatment of diabetic macular edema.

ENDURANCE IIT (NCRVA & Regeneron)

A 2 year investigator initiated study on the long-term efficacy and safety of intravitreal aflibercept (Eylea) injections for the treatment of diabetic macular edema in subjects who completed the three year VISTA-DME trial.

HULK (NCRVA and Regeneron)

A phase I/II, 6 month, open label study of the safety and efficacy of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept for the treatment of diabetic macular edema.

KESTREL CRTH258B2301 (Novartis)

A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase 3 Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema.

PALADIN (Alimera)

A 3 year, phase 4 safety study of IOP signals in patients with DME who are treated with ILUVIEN (fluocinolone acetonide intravitreal implant).

PALM (Allergan)

A phase 2, six month study on the evaluation of Abidipar Pegol (AGN-150998) in patients with decreased vision due to diabetic macular edema.

PROTOCOL U (DRCR Network)

A short-term (9 months) evaluation of combination corticosteroid (Ozurdex) + Anti-VEGF (Lucentis) Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy.

RUBY (Regeneron)

A 9 month, phase 2, randomized, double-masked study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with diabetic macular edema.

VISTA (Regeneron)

A double-masked, randomized, active-controlled, phase 3 study of the efficacy and safety of intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema.